Lineage Cell Therapeutics initiates study of OPC1 for spinal injury

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery System, a novel delivery device developed to deliver OPC1 directly to the area of injury in patients with spinal cord injury. OPC1 is an investigational, allogeneic stem cell-derived cell transplant, comprised of oligodendrocyte progenitor and related glial cells. Improved functional activity can lead to greater mobility and enhanced quality of life for patients and significant cost-savings for caregivers. The DOSED study will enroll both subacute and chronic SCI patients.